The treatment landscape for polycythemia vera is undergoing significant changes as older therapies face patent expiration and newer biologics gain traction. JAKAFI (ruxolitinib) has been the leading treatment for patients resistant or intolerant to hydroxyurea. However, the anticipated arrival of generic ruxolitinib may be delayed, prolonging its market dominance and maintaining high costs for patients and insurers.

The question why is JAKAFI so expensive remains central, with annual treatment costs often exceeding USD 100,000 depending on dose and insurance coverage. Despite assistance programs, the financial burden is significant, particularly for long-term management. A delay in generics means this pressure is likely to continue for years.

Emerging competition includes Besremi (ropeginterferon alfa-2b), which has gained traction following inclusion in the NCCN guidelines. Besremi acts as a long-acting interferon, offering a disease-modifying effect by targeting the underlying clonal proliferation rather than simply controlling symptoms.

Besremi is often considered more cost-effective for chronic use than JAKAFI, though pricing varies geographically. Patients and physicians discuss besremi side effects such as mild flu-like symptoms, fatigue, or liver enzyme changes. Most are manageable, allowing patients to maintain therapy long-term, and its biweekly dosing enhances adherence.

Rusfertide, an injectable hepcidin mimetic from Protagonist Therapeutics, represents another promising approach. Designed to reduce the need for phlebotomy, rusfertide could improve patient quality of life while maintaining hematocrit levels. Clinical trials show encouraging outcomes, although rusfertide FDA approval is still pending.

Despite a regulatory setback from the early withdrawal of Breakthrough Therapy Designation, rusfertide continues to attract strong interest. Its novel mechanism could significantly influence the polycythemia vera interferon therapeutics market, offering patients an alternative to both JAK inhibitors and interferons.

In 2025, the polycythemia vera market is defined by delayed generics, pricing pressures, and the introduction of new therapies. JAKAFI (ruxolitinib) remains a dominant therapy, but Besremi (ropeginterferon alfa-2b) and rusfertide provide growing options for patients and clinicians. Decisions will be shaped by efficacy, safety, and cost considerations, as well as patient preference. The evolving landscape promises more personalized care, though affordability remains a central concern.

Latest Reports Offered By DelveInsight:

Calciphylaxis Market | Carcinoid Tumor Market | Cardiac Arrhythmia Market | Cardiac Insufficiency Market | Cardiac Output Monitor Market | Chronic Pain Market | Dilated Cardiomyopathy Market | Erectile Dysfunction Market | Female Infertility Market | Foot and Ankle Devices Market | Gout Market | Hearing Implants Market | Infusion Pumps Market | Interspinous Spacers Market | Knee Osteoarthritis Market | Knee Reconstruction Devices Market | Metastatic Uveal Melanoma Market | Myeloproliferative Neoplasms Market | Myopia Progression Market Share | Nephroblastoma Market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us 

Kanishk

kkumar@delveinsight.com